Core Viewpoint - The Ministry of Commerce and nine other departments have issued opinions to promote the high-quality development of the retail pharmaceutical industry, focusing on optimizing services and payment methods for insured individuals purchasing medications at designated retail pharmacies [1] Group 1: Policy Enhancements - The opinions emphasize the optimization of outpatient comprehensive services at designated retail pharmacies, allowing insured individuals to purchase medications listed in the medical insurance catalog using prescriptions from designated medical institutions, with costs covered by the medical insurance fund as per regulations [1] - The policy allows for the same medical insurance treatment policies for outpatient comprehensive payment standards, payment ratios, and maximum payment limits at designated retail pharmacies as those applied to grassroots medical institutions in the same region [1] Group 2: Financial and Operational Improvements - The opinions support the use of employee medical insurance personal accounts to cover out-of-pocket medical expenses incurred by insured individuals and their insured close relatives when purchasing medications at designated retail pharmacies [1] - There is a focus on optimizing the settlement methods between the medical insurance fund and retail pharmacies to effectively reduce settlement times and enhance efficiency [1] - The policy aims to optimize the resource allocation planning for designated retail pharmacies, promoting a reasonable layout in conjunction with the construction of convenient living circles [1]

Core Insights - The new drug directory includes 114 newly added drugs, focusing on key areas such as cancer and rare diseases, complementing the basic medical insurance directory [1][2] - The implementation of the updated drug directory will take effect on January 1, 2026, and will be valid until December 31, 2026 [1] Group 1: National Drug Directory Adjustments - A total of 114 drugs have been added to the national directory, with 29 drugs removed; the updated directory now includes 3,253 drugs [2] - Among the newly added drugs, 111 are new products launched within the last five years, with 36 being cancer medications and 10 for rare diseases, enhancing coverage for critical areas [2] - A six-month transition period will be provided for drugs that were removed from the negotiation list to ensure continuity of medication [2] Group 2: Commercial Health Insurance Innovation - The first version of the commercial health insurance innovation drug directory includes 19 drugs, focusing on high-value innovative treatments not fully covered by basic medical insurance [3] - The directory features 9 new drugs and includes 5 CAR-T products, highlighting significant advancements in treatment options [3] - The commercial insurance directory serves as a reference for insurance companies and does not guarantee reimbursement, as it depends on the specific insurance policy [3] Group 3: Payment Standards and Drug Access - The Hunan Provincial Medical Insurance Bureau has established self-payment ratios for the new drug directory, with Class A drugs having a self-payment ratio of 0% [4] - The province aims to facilitate the inclusion of new drugs in hospitals and has mandated local medical insurance departments to guide medical institutions in the proper use of listed drugs [4] - The payment for work-related injury and maternity insurance will not differentiate between Class A and Class B drugs, covering the full cost [4]

Core Insights - The National Medical Insurance Administration held a meeting on December 13, focusing on optimizing the medical insurance payment mechanism during the 14th Five-Year Plan period to promote the development of healthcare and the pharmaceutical industry [1] Group 1: Medical Insurance Policy Changes - A total of 949 new drugs have been added to the medical insurance catalog, bringing the total number of drugs in the catalog to 3,253 [1] - The issuance of measures to support the high-quality development of innovative drugs includes the establishment of a commercial health insurance catalog for innovative drugs, which includes 19 drugs with significant clinical value and high innovation levels [1] Group 2: Payment Mechanism Enhancements - The implementation of disease-based payment has started from pilot programs and is now set for comprehensive coverage, with the introduction of version 2.0 of the disease-based payment scheme [1] - Five supporting mechanisms, including special case negotiations, have been established to alleviate concerns for medical institutions regarding the treatment of critically ill patients and the use of new drugs and technologies [1] Group 3: Financial Relief for Medical Institutions - All coordinated regions across the country will implement immediate settlement, effectively relieving the financial pressure on medical institutions regarding upfront costs [1]